← Evidence map

ArticleDrugs2022

Authors' Reply to Mazza et al.: "Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence".

Eric J Lenze et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Authors' Reply to Mazza et al.: "Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence". | OpenQuestion